CV Sciences, Inc.

CV Sciences is headquartered in the United States and appears to generate most of its business there, with operations and customer demand shaped by U.S. state-level CBD regulation. The company’s primary offices and facilities are in San Diego, California; Grand Junction, Colorado; and Warsaw, Poland, indicating a mix of U.S. commercial and manufacturing/operational support locations. Management also references a globally expanding market, but the disclosed business remains centered on U.S. consumer demand and domestic regulatory conditions. The patchwork of state rules is important because it affects product availability, sales execution, and the risk of out-of-stock situations. The Warsaw, Poland facility suggests some international operating footprint, but no country-level revenue split was disclosed in the provided excerpts.

CV Sciences faces substantial business risk from a fragmented and weakly regulated CBD market, where licensed and illicit competitors can quickly undercut pricing and capture customers. The company has also disclosed temporary manufacturing constraints and out-of-stock issues, which can directly reduce near-term revenue and damage customer retention. Liquidity is a major concern because the company has negative operating cash flow, an accumulated deficit, and dependence on external financing to fund operations. More broadly, CBD and supplement businesses face regulatory uncertainty, product quality and compliance risk, and demand volatility as consumer preferences shift. Any failure to raise capital on acceptable terms could materially affect the company’s ability to continue as a going concern.